Tuesday, 5 February 2019

Dercum’s Disease Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2023

Market Scenario
The global Dercum’s Disease treatment market is expected to register a significant growth during the forecast period (2018–2023).
Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.
Dercum’s Disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the Dercum’s Disease are often short compared to healthy individuals due to bone anomalies.
Key players
Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis,Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, Amgen, Valeant Pharmaceuticals, Syneron Medical, St. Jude Medical Inc. and Alimed, Inc. are some players in the global dercum’s disease market.
Segmentation
The global dercum’s disease market has been segmented into treatment, distribution channel, and end-user.
The market, on the basis of treatment, has been segmented into surgery, medication, liposuction, electrotherapy, acupuncture, and others. The medication segment has been further segmented into diuretics, non-steroidal anti-inflammatory drugs, corticosteroids, and others.
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
The market, by end-user, has been segmented into hospital & clinics, ambulatory surgical centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dercum’s disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European dercum’s disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The dercum’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dercum’s disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global dercum’s disease market owing to a well-established healthcare sector, rising prevalence of rare diseases, and growing healthcare expenditure. According to the data published in the National Center for Biotechnology Information (NCBI) in 2017, about 25 to 30 million American population live with a rare disease. Additionally, favorable reimbursement scenario and a relatively large number of research and development (R&D) activities contribute to the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in the US, the total national health expenditure was USD 3.2 trillion in the year 2015.
Europe is expected to hold the second largest position in the global dercum’s disease market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.
The dercum’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing disposable income, continuously developing economies, and increasing government funding for the healthcare sector. Additionally, regional expansions by market players in the region are considered to be contributing to the market growth.
The Middle East & Africa has the least market share in the global market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dercums-disease-market-6350    
       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Monday, 4 February 2019

Patellar Tendinitis Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

Increasing prevalence of sports injury, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Furthermore, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases are likely to fuel the market growth during the forecast period. Moreover, increasing geriatric population is boost the market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies. However, side-effects and higher treatment cost may hinder the market growth during the forecast period.
The global patellar tendinitis market is expected to grow at a CAGR of ~8.1% during the forecast period 2017-2023.
Tendons are thick cords that attach the muscles to the bones. Inflammation of these tendons is known as tendinitis. Repetitive movement, injury or diseases conditions are main causes of the tendinitis, with severe pain, swelling or tenderness at the affected area. Use of over-the-counter drugs or pain relievers such as non-steroidal anti-inflammatory drugs (NSAIDs), rest therapy and physical therapy are commonly used treatment measures for this condition. Delayed diagnosis of patellar tendinitis may require a surgery to reduce pain, and improve the movement. Tendinitis is found to be prevalent among athletes or sports players as a result of continuous strain on the tendons due to a rigorous workout, running and other activities. Moreover, patellar tendinitis is an injury to the tendon connecting kneecap (patella). The patellar tendon works with the muscles at the front of the thigh to knee. Patellar tendinitis or tendonitis is also known as jumper's knee and is most common in athletes whose sports involve frequent jumping such as basketball and volleyball. However, even people who don't participate in jumping sports can get patellar tendinitis
Competitive Dashboard:
Some of key the players in the market are Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy) and others.
Segmentations
The global patellar tendinitis market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of the diagnosis, it is segmented into the physical examination, imaging tests, and others. The imaging test is further segmented into X-rays, Ultrasound, and Magnetic resonance imaging (MRI).
The treatment segment is divided into corticosteroid injection, platelet-rich plasma injection, surgery, Medical devices, and others. The medical devices are further segmented into the mechanical band, support tape, pre-cut strips, continuous rolls, and others.
Based on the end user, it is segmented into hospitals & clinics, research laboratories, and others.
Major Regional Analysis:
The Americas dominate the global patellar tendinitis market owing to well-developed technology, increasing patient population for sports injury, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region. 
Europe holds the second position in the global patellar tendinitis market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.    
The Asia Pacific is the fastest growing patellar tendinitis market owing to the presence of rapidly developing healthcare technology and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/patellar-tendinitis-market-5134

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future,
Office No. 528, Amanora Chambers,
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Evans Syndrome Market - Granular Market Report and Review, 2018

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/evans-syndrome-market-5136   

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Evans Syndrome Market - Granular Market Report and Review, 2018

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/evans-syndrome-market-5136   

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cowden Syndrome Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario:
Cowden syndrome is part of the PTEN hamartoma tumor syndrome. Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin. The global Cowden syndrome market is expecting a healthy growth in the coming future. The global market is majorly driven by increasing Cowden syndrome patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, long time for approval and side effects of the treatment may hinder the growth of the market.
The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.
Key Players
Some of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)
Regional Analysis
The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.
And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.
Segmentation
The global Cowden syndrome market is segmented on the basis of site, treatment and end users.
On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.
On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Agnosia Treatment Market Share, Opportunities, Segmentation and Forecast to 2023

Market Scenario
Agnosia is a rare neurological condition in which an individual may face difficulty to process sensory information like recognizing a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.
People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.
Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.
The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).
Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.
There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.
Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
The global market of agnosia treatment is expected to grow at a CAGR of approximately 7.2% during the forecast period 2017-2023.
Key Players
Some of key the players in the global agnosia treatment market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.),  Lupin ltd. (India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA Labs ltd. (India) and others.
Segmentation
The agnosia treatment market is segmented on the basis of is segmented on the basis of diagnosis, causes, type, and treatment.
On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.
On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia
On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole
Regional Analysis
The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.
Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.
Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/agnosia-treatment-market-5045  

  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Latest Study Offers Detailed Insights on Anoxia Market 2018

Market Scenario
Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.
Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.
Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.
Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.
Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.
It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Segmentation
The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.
On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).
On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.
On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.
Regional Analysis
The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for anoxia due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.
        
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)